Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECST-HIV
NCT06402383Active, not recruiting
- Start
- May 2024
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Randomised, open-label trial of human papillomavirus vaccine in Cervical Cancer (CC) (2 arms). Primary endpoint: Evidence Generation for use of a 4-step HPV testing, triage and vaccinate strategy at 15 months. Started May 2024; status: active, not recruiting.
02
Drugs
human papillomavirus vaccine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06402383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06402383.